Bioinformatics and computational biology are now at the center of experiment design, hypothesis generation, and rebuilding biological systems. By 2026, the spread of high-throughput sequencing and the use of multi-omics in clinical and research settings have caused a very fast growth in data production.
This growth is not only about size but also about resolution. Single-cell data, spatial transcriptomics, and multimodal measurements make it possible to see biological systems in much more detail. However, this large amount of data cannot be handled well with traditional statistical methods. At this point, generative AI and large language models are not only tools for analysis, but systems that help understand data and design new biological structures.
From a research point of view, one of the biggest changes is how hypotheses are created. In the past, research followed a linear path: observation, hypothesis, then experimental validation. Today, this process is becoming a closed-loop system. AI models learn from large datasets and predict possible biological relationships. These predictions are tested in experiments, and the results are fed back into the model. This makes the research cycle faster and more dynamic.
In this context, biological foundation models are creating a major shift in research methods. Models like AlphaFold 3 do not only predict protein structures, but also model interactions between proteins, DNA, and ligands. Models like ESM3 can learn the relationship between sequence, structure, and function, and even design new proteins. Evo 2 goes further by working directly on DNA and simulating evolutionary processes. These developments show that biology is becoming a programmable system.
Experimental Validation, Clinical Reality, and Infrastructure Limits
In drug discovery, AI has the strongest impact in early stages. The time needed to develop candidate molecules has decreased from years to months. However, there is an important limitation. AI can speed up discovery, but biological validation still takes time. Clinical processes, patient differences, and toxicity risks mean that experiments are still necessary. For researchers, AI should be seen as a tool to explore more possibilities, not as a final answer.
One major challenge is the gap between dry lab and wet lab. AI can generate thousands of candidates very quickly, but testing them in the lab takes time and resources. Autonomous laboratories are being developed to solve this problem. These systems use robotics, real-time data analysis, and AI to create continuous and optimized experiment cycles. Still, their success depends on good experiment design and meaningful hypotheses, which keeps the researcher in a key role.
Advances in multi-omics and single-cell data are also changing how we understand biological systems. Spatial transcriptomics helps us see not only what cells do, but also where they are and how they interact. This is very important in complex systems like tumors. However, combining and analyzing this type of data is difficult. Generative AI helps integrate and interpret these datasets, making research more efficient.
Rare diseases and variant interpretation are also important areas. After genome sequencing, many genetic variants are found, but most of them are not clearly understood. Evolution-based models and large datasets help predict their effects more accurately. Still, clinical interpretation requires human expertise. AI supports decisions, but does not replace researchers.
From Computational Biology to Programmable Biology
This transformation also creates new needs in research infrastructure. Training and running biological models require strong computing power and cloud systems. Because of this, the role of a bioinformatician is changing. It is no longer only about data analysis. It now includes data architecture, model evaluation, and managing large-scale computing systems. This creates a more hybrid role.
At the same time, regulation and data management are becoming more important. Health data is considered high-risk, so transparency and security are required. Genetic data is also becoming a geopolitical issue, which affects data sharing and international collaboration. Researchers now need to understand not only technology, but also regulations.
Overall, AI is not just speeding up bioinformatics. It is changing how research works. Hypothesis generation, experiment design, and data analysis are no longer separate steps, but parts of a connected system. In this system, the role of the researcher is still critical. Choosing the right questions and understanding biological meaning are still human responsibilities. AI makes the process faster and broader, but real scientific progress still starts with asking the right question.
Geschrieben von
Solvien Team